Bioverativ, A Sanofi Company company information, Employees & Contact Information

Sanofi snaps up Biogen's spun-out Bioverativ in $11.6B deal Fierce Pharma

Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock Biogen

Sanofi to Acquire Bioverativ for $11.6 Billion GlobeNewswire

Sanofi’s Bioverativ deal begins to pay dividends with first new drug approval BioPharma Dive

Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia PR Newswire

A €344M Partnership will Develop Bicycle Drugs for Hemophilia Labiotech.eu

Biogen dubs publicly traded hemophilia spinoff Bioverativ, aims for early 2017 Fierce Biotech

Sanofi CEO Finally Scores With $11.6B Buyout of Biogen’s Spinoff Bioverativ BioSpace

Biogen Spin-Off Bioverativ To Be Acquired Forbes

Sanofi is buying Bioverativ for $11.6 billion businessinsider.com

Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock Biogen

Sanofi beefs up pipeline with $11B Bioverativ buy BioPharma Dive

Sanofi EVP's Bioverativ blabbing ends in insider trading cases Fierce Pharma

Bioverativ says data back twice-a-month dosing for hemophilia A drug Fierce Biotech

Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company Biogen

Bioverativ buys True North, and may forge ahead with more rare disease M&A BioPharma Dive

SEC sues over suspected insider trading around Sanofi's Bioverativ buy Fierce Pharma

Biogen Completes Separation of Global Hemophilia Business, Bioverativ Biogen

Bioverativ taps new manufacturer as it steps out of Biogen’s shadow BioPharma Dive

How did Sanofi win over Bioverativ? It upped its bid—and called on activist investor Alex Denner Fierce Pharma

Sanofi boosts presence in haemophilia, rare blood disorders with deal to buy Bioverativ for $11.6 billion FirstWord Pharma

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial ScienceDirect.com

Sanofi Snaps Up Bioverativ for $11.6B, Boosting Hemophilia and Rare Disease Offerings Genetic Engineering and Biotechnology News

Ex-Bioverativ CEO John Cox lands at T-cell biotech Torque Therapeutics Fierce Biotech

Sanofi takes $2B hemophilia write-down as Roche's Hemlibra brings the heat Fierce Pharma

Sanofi, Facing Threat From Generics, Moves to Buy Hemophilia Drug Maker (Published 2018) The New York Times

Sanofi's Eloctate, a Bioverativ buyout centerpiece, suffers on Roche's Hemlibra launch Fierce Pharma

Sanofi to acquire haemophilia specialists Bioverativ for $11.6bn European Pharmaceutical Review

Activist investor Alex Denner, Bioverativ shareholder reach tentative settlement in insider trading case statnews.com

Hemophilia newcomer Bioverativ aims to keep parent Biogen's 'patient-centric' corporate image Fierce Pharma

Sanofi's Enjaymo, once a jewel in its Bioverativ buyout, finally wins its FDA nod for a rare blood disorder Fierce Pharma

Bioverativ to buy True North for $400M upfront Fierce Biotech

Pre-Issuance, Industry-Standard Monitoring and Copying of a Product Does Not Support a Finding of Willful Infringement of Method of Use Patent akingump.com

Bioverativ executive Rogerio Vivaldi to helm cell therapy producer Sigilon Fierce Biotech

Cowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up Yahoo Finance

Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ Investor's Business Daily

Sarissa Capital, Founder Settle Bioverativ Suit In Del. For $40M Law360

In Latest Lateral Payoff, Paul Weiss Grabs Role in Bioverativ Sale Law.com

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Fierce Pharma

Biogen Hemophilia Spinoff Bioverativ Begins Trading Shares Genetic Engineering and Biotechnology News

Sanofi to buy Bioverativ for $11.6bn Financier Worldwide

Denner, Sarissa Will Pay $40 Million to End Bioverativ Deal Case Bloomberg Law News

Bioverativ–True North Therapeutics: Stronger Research Pipeline Market Realist

This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver Market Realist

Sanofi expands footprint in Mass. with $11.6 billion purchase of Waltham-based Bioverativ The Boston Globe

Bioverativ Expected to Report Robust Revenue Growth in 2017 Market Realist

Sanofi to buy Bioverativ for $11.6 B BioSpectrum India

Sanofi chief delivers a $11.6bn Bioverativ deal after striking out twice| Gulf Times Gulf Times